copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
DURECT | Unlocking the potential of epigenetic therapeutics DURECT harnesses epigenetic modulation to potentially treat serious and life-threatening conditions, including acute organ injury and cancer Our unique approach targeting dysregulated DNA methylation has the potential to change the course of disease and improve patients’ lives
Investors - DURECT DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer
About Us - DURECT We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits You can allow the use of all cookies by clicking “Accept All” If you would like to refuse all non-essential cookies, you can do so by clicking “Decline All” You can manage and withdraw your consent at any time using our cookie consent tool found here in Cookie Settings
DURECT Corporation Reports First Quarter 2025 Financial Results and . . . DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury
News - DURECT DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
DURECT Corporation to Announce Third Quarter 2024 Financial Results and . . . CUPERTINO, Calif , Nov 6, 2024 PRNewswire — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter
DURECT Corporation Receives FDA Breakthrough Therapy Designation for . . . DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer
DURECT Corporation Reports First Quarter 2024 Financial Results and . . . DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 . . . CUPERTINO, Calif , March 19, 2025 PRNewswire — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the
DURECT CORPORATION DURECT is pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer